Clodronate: A Review of its Pharmacological Properties and Therapeutic Efficacy in Resorptive Bone Disease

Drugs

Volumn 47, Issue 6, 1994, Pages 945-982

  Plosker, Greg L ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL AFFECTING AGENT; CLODRONIC ACID;

BONE DISEASE; BONE METASTASIS; BREAST CANCER; CALCIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; HUMAN; HYPERCALCEMIA; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PROSTATE CARCINOMA; REVIEW; SIDE EFFECT;

ANIMAL; BONE NEOPLASMS; BONE RESORPTION; CALCINOSIS; CLINICAL TRIALS; CLODRONIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMAN; HYDROXYPROLINE; HYPERCALCEMIA; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; NEOPLASMS; OSTEITIS DEFORMANS; OSTEOPOROSIS; TISSUE DISTRIBUTION;

EID: 0028285203     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199447060-00007     Document Type: Article

References (259)

1. Metastasis in carcinoma: analysis of 1000 autopsied cases
2. Sequential treatment of Paget’s disease with human calcitonin and dichloromethylene diphosphonate (CI2MDP)
3. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy
4. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma
5. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment
6. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton
7. Mineralisation defects with Pamidronate therapy for Paget’s disease
8. A new therapeutic approach to osteoporosis associated with juvenile chronic arthritis (JCA)
9. Influence of disodium etidronate on clinical and laboratory manifestations of Paget’s disease of bone
10. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
11. Treatment of Paget’s disease of bone with intravenous infusion of second-generation biphosphonate
12. Effects of a new aminodiphosphonate (aminohydroxybu-tylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis
13. Clinical manifestations of cancer-related hypercalcemia
14. Double-blind placebo-controlled trial of bonefos (clodronate) in malignant hypercalcaemia. Abstract
15. Structure of disodium dihydrogen 1-hydroxyethylidenediphosphonate tetrahydrate: a bone growth regulator
16. Improvement in the deformity of the face in Paget’s disease treated with diphosphonates
17. Malignant hypercalcemia — a hospital survey
18. Bone and renal components in hypercalcaemia of malignancy and responses to a single infusion of clodronate
19. Pathophysiological aspects and therapeutic approaches of tumoral osteolysis and hypercalcemia
20. Two models of action of bisphosphonates on osteoclastic resorption of mineralized matrix
21. Cytogenetic investigations of patients on clodronate therapy for Paget’s disease of bone
22. Disodiumclodronate and radiotherapy for bone metastases from solid tumors
23. Renal failure associated with intravenous bisphosphonates
24. Clodronate for the management of pain in endosteal hyperostosis. Abstract
25. Inhibition of bone mineral loss during lactation by CI2MBP
26. Dichloromethylene diphosphonate action in hematologic and other malignancies
27. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro
28. Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage
29. Dichloromethylene-diphosphonate in the treatment of osteolytic metastases
30. Sustained biochemical effects of short treatment of Paget’s disease of bone with dichloromethylene diphosphonate
31. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases
32. Treatment of postmenopausal osteoporosis: some current concepts
33. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications
34. IV dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation
35. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy
36. Clodronate kinetics and dynamics
37. Clodronate treatment increases serum osteocalcin in normocalcemic osteolytic bone metastases
38. Severe hypercalcaemia four months after acute oliguric renal failure — successful treatment with intravenous clodronate
39. Osteopenia in systemic mastocytosis: natural history and responses to inhibitors of bone resorption
40. The effects of thionapthene-2-carboxylic acid-lysine on the hypercalcemia of malignancy in the rat
41. The use of clodronate in multiple myeloma
42. Paradoxical acute hypercalcemic effect of salmon calcitonin in patients having Paget’s disease of bone after treatment with dichloromethylene diphosphonate
43. Dichloromethylene diphosphonate (CI2MDP) treatment of hypercalcaemia produced from bone metastases
44. Long term effects of dichloromethylene diphosphonate in Paget’s disease of bone
45. Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma
46. Results of prolonged treatment of Paget’s disease of bone with disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP)
47. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium Pamidronate); non-linear increase of lumbar bone mineral density
48. Intravenous administration of clodronate in normocalcemic patients with tumoral bone metastases: effect on serum parathormone and biochemical markers of bone turnover
49. Human parathyroid hormone 1-34-mediated hypercalcemia in a rat model, and its inhibition by dichloromethane diphosphonate
50. Spinal cord dysfunction in Paget’s disease of bone. Has medical treatment a vascular basis?
51. Biochemical and clinical responses to dichloromethylene diphosphonate (CI2MDP) in Paget’s disease of bone
52. Effect of dichloromethylene diphosphonate in Paget’s disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease
53. Drug treatment of primary hyperparathyroidism: use of clodronate disodium
54. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates
55. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
56. Treatment of skeletal disease in breast cancer: a controlled clodronate trial
57. Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone
58. Clodronate for osteolytic metastases due to breast cancer
59. Osteolytic bone metastasis in breast carcinoma: pathogenesis, morbidity and bisphosphonate treatment
60. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain
61. The effects of two diphos-phonates on bone metabolism in the rat
62. Effect of dichloromethylene diphosphonate on bone metabolism in calcium and phosphorus-depleted rats
63. Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells
64. The effect of diphosphonates on periosteal and bone cells in culture
65. The effect of bisphosphonates on glycolysis in cultured calvaria cells and their homogenate
66. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes
67. Hypercalcaemia — a hospital survey
68. Pamidronate
69. Dichloromethylenebisphosphonate (CI2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone
70. Bisphosphonates
71. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo
72. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo
73. Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis
74. Absorption of oral diphosphonate in normal subjects
75. Lack of variation of plasma beta-endorphin after clodronate infusion in patients with increased bone resorption
76. Treatment of bone metastases with dichloromethylene bisphosphonate
77. Chemical, biochemical and medicinal properties of the diphosphonates
78. The anatomy and pathways of skeletal metastasis
79. The effect of prostaglandin synthesis inhibitors and diphosphonates on tumour-mediated osteolysis
80. Rapid intracellular degradation of newly synthesized collagen by bone cells — effect of dichloromethylenebisphosphonate
81. The influence of two diphosphonates on calcium metabolism in the rat
82. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss
83. Studies on the regulation of bone synthesis and bone resorption
84. Histologic study of the inhibition of bone resorption in organ cultures by myoinositol-2-monophosphate
85. The progress of the periodontal syndrome in the rice rat
86. Duration of effect of oral diphosphonate therapy in Paget’s disease of bone
87. Differential response of bone cells isolated by sequential digestion to dichloromethylene-bisphonate in culture
88. Effects of 1-hydroxy ethane-1,1-diphosphonate and dichloromethanediphosphonate on rabbit articular chondrocytes in culture
89. The effects of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on collagen synthesis by rabbit articular chondrocytes and rat bone cells
90. Diphosphonate treatment of Paget’s disease of bone
91. Clodronate in the medical management of hyperparathyroidism
92. Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure
93. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days
94. Clodronate: an effective agent for the treatment of increased bone resorption
95. Relation between signs and symptoms in Paget’s disease of bone
96. Results of treating tumour-induced hypercalcaemia with clodronate alone
97. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy
98. Sodium clodronate in a patient with the Eisenmenger syndrome, hyperparathyroidism and multiple endocrine adenomatosis
99. Resorption is not essential for the stimulation of bone growth by HPTH-(1-34) in rats in vivo
100. Traitement par le clodronate de l’hypercalcémie d’origine hyperparathyroïdienne
101. Comparative effects of cetaben (PHB) and dichloromethylene diphosphonate (CI2MDP) on the development of atherosclerosis in the cynomolgus monkey
102. Paget’s disease of bone: an update on management
103. Advances in the management of Paget’s disease of bone
104. Rehydration in the treatment of severe hypercalcaemia
105. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow
106. An assessment of the interaction between human neutrophils, hydroxyapatite and dichloromethylene bisphosphonate in vitro: and electron microscopic and chemilumi-nescence study
107. Influence of dichloromethylene bisphosphonate on the in vitro phagocytosis of hydroxyapatite particles by rat peritoneal exudate cells: an electron microscopic and chemiluminescence study
108. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate
109. Modulation of hypercalcemia by dichloromethane diphosphonate and by calcitonin in a model of chronic primary hyperparathyroidism in rats
110. Effect of dichloromethane diphosphonate on cortisol-induced bone loss in young adult rabbits
111. The treatment of osteoporosis with disodium ethane-1 -hydroxy-1,1 -diphosphonate
112. Comparison of two parenteral diphosphonates in hypercalcaemia of malignancy
113. Effet de deux diphosphonates sur la lyse osseuse induite par des extraits tumoraux
114. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals
115. Inhibition by diphosphonates of bone resorption induced by the walker tumor of the rat
116. Use of dichloromethylene diphosphonate in metastatic bone disease
117. Inhibition by two diphosphonates of bone lysis in tumor-conditioned media
118. Traitement par deux diphosphonates des hypercalcémies d’origine tumorale
119. Use of dichloromethylene diphosphonate in metastatic bone disease
120. The use of clodronate in disorders of calcium and skeletal metabolism
121. Clodronate in hypercalcaemia and osteolytic bone disease due to breast cancer
122. Use of diphosphonates in hypercalcaemia due to malignancy
123. Rationale for the use of clodronate in osteoporosis
124. Effects of intravenous diphosphonates on renal function
125. Assessment of optimum duration of therapy with oral dichloromethylene diphosphonate (clodronate) in the treatment of Paget’s disease
126. Diphosphonates inhibit human osteoblast secretion and proliferation
127. Effects of disodium ethane-1-hydroxy-1,1-diphosphonate on bone formation
128. Established adjuvant arthritis (AA) can be treated by systemic application of clodronate containing multilamellar liposomes
129. Clodronate treatment for Paget’s disease of the bone
130. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish prostate cancer group
131. Clodronate for multiple myeloma
132. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
133. Comparison of the effects of ethane-1-hydroxy-1,1-diphosphonate and dichloromethylene diphosphonate upon periodontal bone resorption in rice rats
134. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate
135. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro
136. Parathyroid-hormone-induced metabolic alkalosis in dogs
137. Treatment with clodronate in patients with hypercalcemia secondary to malignancy
138. Comparative effects of calcitonin and clodronate in hypercalcemia
139. Bisphosphonates can reduce osteoclastic bone resorption by two different mechanisms
140. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate
141. Disodium clodronate in the treatment of pain due to bone metastases
142. Parathyroid hormone-related protein in hypercalcaemia of malignancy
143. The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat leydig cell tumor
144. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton
145. Severe hypocalcaemia after treatment with oral clodronate and aminoglycoside
146. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man
147. Diphosphonates and phosphate homoeostasis in man
148. The effects of disodium ethane-hydroxy-1,1-diphosphonate and disodium dichloromethylene diphosphonate on lanthanide-induced calcergy
149. The effects of various anti-calcific, anti-rheumatic and anti-inflammatory drugs on local (simple) calcergy induced by lead acetate in the mouse
150. Skeletal muscle calcergy
151. The effect of diphosphonates on heterotopic ossification in regenerating achules tendon of the mouse
152. Long-term effects of parenteral dichloromethylene bisphosphon-ate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy
153. Effects of disodium dichloromethylene diphosphonate on Paget’s disease of bone
154. Tolerability and safety of clodronate therapy in bone diseases
155. Ethane-1-hydroxy-1,1-diphosphonate (EHDP) effects on growth and modelling of the rat tibia
156. The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat
157. Effects of clodronate and etidronate on growing rat tibia
158. Cutaneous calciphylactic reactions in the mouse and the rat and the effects of diphosphonates on the reaction in the rat
159. Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients
160. Effects of clodronate on immobilization bone loss
161. A one year follow-up study of the distribution ofl C-clodronate in mice and rats
162. The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron
163. Comparison of the distribution of three bisphosphonates in mice
164. The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro
165. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice
166. 14C] clodronate (dichloromethylene bisphosphonate) disodium in mice
167. Overview of cancer-related hypercalcemia: epidemiology and etiology
168. The effects of diphosphonates, polyphosphates, and calcitonin on “immobilisation osteoporosis” in rats
169. Pathophysiology of cancer-associated hypercalcemia
170. The hypercalcemia of malignancy: pathogenesis and management
171. Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases
172. Bone resorption in orthotopic and heterotopic bone of dichloromethylene bisphosphonate-treated rats
173. Single-dose intravenous therapy with Pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages
174. Clodronate reduces plate osteopenia in the rabbit
175. Inhibition of post-extraction alveolar ridge resorption in rats by dichloromethane diphosphonate
176. Renal and nonrenal clearance of clodronate in patients with malignancy and renal impairment
177. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate
178. Level of clodronate in bone after single and repeated subcutaneous injections in rats
179. Erythroderma after clodronate treatment
180. Clodronate inhibits contraction and prevents the action of 1-type calcium channel antagonists in vascular smooth muscle
181. Drugs used in the treatment of metabolic bone disease
182. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma
183. Bone metastases in breast cancer, prostate cancer and myeloma
184. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
185. Results of a randomized study of clodronate in treating cancer-related hypercalcemia
186. Severe hypoglycaemia after treatment with diphosphonate and aminoglycoside
187. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould dictyostelium discoideum
188. Pharmacokinetics of clodronate in patients with metastatic breast cancer
189. Treatment of malignant hypercalcaemia with clodronate
190. Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption
191. Mechanisms of malignant hypercalcaemia in carcinoma of the breast
192. Hypercalcaemia of malignancy
193. Effects of diphosphonate and x-rays on bone lesions induced in rats by prostate cancer cells
194. Symptomatic hypercalcaemia in lung cancer
195. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy
196. Hypercalcaemia of malignancy: evidence for a non-parathyroid humoral agent with an effect on renal tubular handling of calcium
197. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia
198. Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy
199. Clodronate treatment in patients with malignancy-associated hypercalcemia
200. The effects of two diphosphonates on the resorption of mouse calvaria in vitro
201. Usefulness of chlodronate (C12MDP) for the therapy of postmenopausal primary hyperparathyroidism
202. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate
203. The walker 256/B carcinosarcoma in thy-roparathyroidectomized rats: a model to evaluate inhibitors of bone resorption
204. Bisphosphonate-induced broncho-constriction in aspirin-sensitive asthma
205. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases — a prospective randomised placebo-controlled multicentre study
206. The alteration of osteoclast morphology by diphosphonates in bone organ culture
207. Inhibition of bone resorption by difluoro-methylene diphosphonate in organ culture
208. Pyrophosphate and diphosphonates in skeletal metabolism
209. Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone
210. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxy-apatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats
211. Diphosphonates in Paget’s disease
212. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
213. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy
214. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloro-methylene diphosphonate (CI2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats
215. The effects of diphosphonates on alveolar bone loss
216. Influence of dichloromethylene diphosphonate on reactive oxygen species production by human neutrophils
217. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism
218. Therapy of hypercalcaemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate
219. Structure-activity relationship of various bisphosphonates
220. Antiresorptive dose-response relationships across three generations of bisphosphonates
221. Case report: chronic lymphocytic leukemia and hypercalcemia: treatment with dichloromethylene diphosphonate
222. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton
223. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma
224. Diphosphonates are potent inhibitors of mammalian inorganic pyrophosphatase
225. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
226. Bisphosphonates inhibit 1,25-dihydroxyvitamin D3-in-duced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro
227. Effect of bisphos-phonates on osteoclast number and bone resorption in the rat. Abstract
228. Diphosphonates for otospongiosis
229. Comparative effects of clodronate and calcitonin on bone metastatic breast cancer: a histomorphometric study
230. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP
231. Interference of dichloromethane diphosphonate with parathyroid hormone effects at the bone but not at the kidney level
232. Treatment of the hypercalcaemia of malignancy with intravenous clodronate
233. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD
234. Reversible depletion of synovial lining cells after intra-articular treatment with liposome-encapsulated dichloromethylene diphosphonate
235. Role of synovial macrophages in experimental arthritis
236. In vivo role of phagocytic synovial lining cells in onset of experimental arthritis
237. Role of phagocytic synovial lining cells in experimental arthritis
238. Extracellular and intracellular action of clodronate in osteolytic bone diseases? A hypothesis
239. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated DMDP
240. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate
241. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate
242. Untreated Paget’s disease of bone, studied by scintigraphy
243. Comparative effects of APD and CI2MDP on bone in the rat: in vivo and in vitro studies
244. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma
245. Clodronate for palliative treatment of bone metastases in prostatic cancer
246. Familial expansile osteolysis
247. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
248. Interaction of dichloromethylene diphosphonate and vitamin D on bone of thyropara-thyroidectomized rats
249. A scanning electron-microscopic study of femoral bone surfaces from castrate rats treated with dichloromethylene biphosphonate
250. The effects of dichloromethylene biphosphonate on osteoporotic femora of adult castrate male rats
251. Clodronate
252. Clodronate kinetics and bioavailability
253. Effect of dichloromethane diphosphonate on calcium homeostatic mechanisms in pregnant cows
254. Immobilisation hypercalcaemia in adults and treatment with clodronate
255. Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone
256. Treatment of tumor hypercalcemia with clodronate